424 related articles for article (PubMed ID: 23617429)
21. [Development and clinical application of novel proteasome inhibitors].
Iida S
Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
[No Abstract] [Full Text] [Related]
22. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
23. Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.
Mirabella AC; Pletnev AA; Downey SL; Florea BI; Shabaneh TB; Britton M; Verdoes M; Filippov DV; Overkleeft HS; Kisselev AF
Chem Biol; 2011 May; 18(5):608-18. PubMed ID: 21609842
[TBL] [Abstract][Full Text] [Related]
24. Update on the proteasome inhibitor bortezomib in hematologic malignancies.
Goy A; Gilles F
Clin Lymphoma; 2004 Mar; 4(4):230-7. PubMed ID: 15072615
[TBL] [Abstract][Full Text] [Related]
25. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells.
Skrott Z; Cvek B
Mini Rev Med Chem; 2012 Oct; 12(12):1184-92. PubMed ID: 22931589
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibitors as therapeutics.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
[TBL] [Abstract][Full Text] [Related]
27. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
28. Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
O'Connor O; Wright J; Moskowitz CH; Muzzy J; MacGregor-Cortelli B; Hamlin P; Straus D; Trehu E; Schenkein DP; Zelenetz AD
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S21-2. PubMed ID: 19791425
[TBL] [Abstract][Full Text] [Related]
29. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
31. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
O'Connor OA
Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib combination therapy in multiple myeloma.
Kapoor P; Ramakrishnan V; Rajkumar SV
Semin Hematol; 2012 Jul; 49(3):228-42. PubMed ID: 22726546
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
Tobinai K
Int J Clin Oncol; 2007 Oct; 12(5):318-26. PubMed ID: 17929113
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Koprivnikar JL; Cheson BD
Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439
[TBL] [Abstract][Full Text] [Related]
35. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
[TBL] [Abstract][Full Text] [Related]
36. Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Mujtaba T; Dou QP
Discov Med; 2011 Dec; 12(67):471-80. PubMed ID: 22204764
[TBL] [Abstract][Full Text] [Related]
37. Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Lonial S; Boise LH
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():25-31. PubMed ID: 25188480
[TBL] [Abstract][Full Text] [Related]
38. Macrocyclic proteasome inhibitors.
Krahn D; Ottmann C; Kaiser M
Curr Med Chem; 2011; 18(33):5052-60. PubMed ID: 22050753
[TBL] [Abstract][Full Text] [Related]
39. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
40. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
Hellmann A; Rule S; Walewski J; Shpilberg O; Feng H; van de Velde H; Patel H; Skee DM; Girgis S; Louw VJ
Clin Pharmacokinet; 2011 Dec; 50(12):781-91. PubMed ID: 22087865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]